Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 4 | 2023 | 43 | 1.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 101 | 0.720 |
Why?
|
| Desensitization, Immunologic | 1 | 2023 | 116 | 0.710 |
Why?
|
| Premenopause | 1 | 2015 | 33 | 0.440 |
Why?
|
| Adnexal Diseases | 1 | 2015 | 22 | 0.430 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1826 | 0.400 |
Why?
|
| Endometrial Neoplasms | 3 | 2020 | 110 | 0.350 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1586 | 0.250 |
Why?
|
| Lymph Node Excision | 2 | 2016 | 159 | 0.220 |
Why?
|
| Uterine Neoplasms | 2 | 2015 | 100 | 0.200 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 420 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2015 | 564 | 0.160 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2017 | 11 | 0.140 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2017 | 50 | 0.140 |
Why?
|
| Brachytherapy | 1 | 2018 | 85 | 0.130 |
Why?
|
| Salpingo-oophorectomy | 1 | 2017 | 10 | 0.130 |
Why?
|
| Peritoneum | 1 | 2017 | 34 | 0.130 |
Why?
|
| Omentum | 1 | 2017 | 40 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 369 | 0.120 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2015 | 17 | 0.110 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 30 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 92 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 46 | 0.110 |
Why?
|
| Cyclic S-Oxides | 1 | 2014 | 2 | 0.100 |
Why?
|
| Thiadiazoles | 1 | 2014 | 4 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2014 | 111 | 0.100 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2015 | 66 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 58 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 78 | 0.100 |
Why?
|
| Gynecology | 1 | 2015 | 124 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 154 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2015 | 245 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2014 | 202 | 0.090 |
Why?
|
| Female | 11 | 2023 | 70963 | 0.090 |
Why?
|
| SEER Program | 3 | 2020 | 214 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 293 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 555 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 943 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 523 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1287 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2550 | 0.070 |
Why?
|
| Survival Rate | 3 | 2020 | 2114 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 21025 | 0.070 |
Why?
|
| Humans | 11 | 2023 | 131163 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 972 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6797 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 442 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3763 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 3147 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 1272 | 0.040 |
Why?
|
| Middle Aged | 5 | 2018 | 28601 | 0.040 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 16 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 31282 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 5063 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2018 | 17753 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 108 | 0.030 |
Why?
|
| United States | 3 | 2020 | 12072 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 49 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 55 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 60 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 78 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 66 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 129 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 156 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 4886 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 63 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 387 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 274 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 426 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 713 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 168 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2015 | 357 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 975 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1216 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 577 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1378 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 10103 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1797 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1345 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1336 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3748 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5196 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 3711 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2602 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 6099 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 11074 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 4686 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 12936 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 18301 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 33912 | 0.010 |
Why?
|